Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells.

Autor:	Vora AA; Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA., Mondala PK; Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA., Costello C; Division of Blood and Marrow Transplantation, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.; Moores Cancer Center at University of California, San Diego, La Jolla, CA 92093, USA., MacLeod AR; Ionis Pharmaceuticals, Carlsbad, CA 92008, USA., Crews LA; Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.; Moores Cancer Center at University of California, San Diego, La Jolla, CA 92093, USA.
Jazyk:	angličtina
Zdroj:	STAR protocols [STAR Protoc] 2021 May 27; Vol. 2 (2), pp. 100565. Date of Electronic Publication: 2021 May 27 (Print Publication: 2021).
DOI:	10.1016/j.xpro.2021.100565
Abstrakt:	Interferon regulatory factor 4 (IRF4) is a transcription factor that regulates normal and malignant immune cell development and is implicated in multiple myeloma pathogenesis. This protocol describes the use of combined cell surface and intranuclear staining with fluorescent antibodies to measure IRF4 protein expression within myeloma and normal immune cells. IRF4 protein quantification may provide a valuable prognostic tool to predict disease severity and sensitivity to IRF4-targeted therapies. This flow-cytometry-based procedure could also be rapidly translated into a clinically compatible assay. For complete details on the use and execution of this protocol, please refer to Mondala et al. (2021). Competing Interests: A.R.M. is an employee of Ionis Pharmaceuticals. All other authors declare no competing interests. (© 2021 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu